Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Shire : Files 8K - Other Events

share with twitter share with LinkedIn share with facebook
share via e-mail
02/17/2017 | 07:24pm CEST

Shire PLC (SHPG) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on February 17, 2017.

Shire plc has issued the press release attached hereto as Exhibit 99.1 which is incorporated by reference herein.

The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/936402/000095010317001531/dp73113_8k.htm

Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/936402/000095010317001531/0000950103-17-001531-index.htm

Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIRE
10/19 SHIRE : Create the Soundtrack to Your Unique Day with “Compose Your Life&r..
10/18 FTSE rises to record close, blue-chips shrug off Reckitt blip
10/17 SHIRE : New Formulation of ONCASPAR Receives Positive CHMP Opinion in Europe for..
10/14 SHIRE : Activist fund seeks break-up of £35bn pharma group Shire
10/13 SHIRE PLC : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP O..
10/13 SHIRE : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP Opini..
10/12 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
10/12 SHIRE : to announce third quarter 2017 results
10/12DJSHIRE PLC SHIRE PLC : Notice Of Results
10/12 SHIRE PLC : Notice of Results
More news
News from SeekingAlpha
10/20 Debt-laden pharmas under pressure on Concordia's debt restructuring
10/19 Premarket analyst action - healthcare
10/18 Generic Restasis Risk Metastasizes To Shire
10/18 Shire feels Amgen's Restasis patent pain, shares down 3%
10/16 YOUR DAILY PHARMA SCOOP : ACRX Second Chance, AERI Rhopressa Success, Aratana EN..
Financials ($)
Sales 2017 14 973 M
EBIT 2017 5 586 M
Net income 2017 2 577 M
Debt 2017 19 246 M
Yield 2017 0,73%
P/E ratio 2017 16,76
P/E ratio 2018 12,05
EV / Sales 2017 4,29x
EV / Sales 2018 3,87x
Capitalization 44 964 M
Duration : Period :
Shire Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Technical analysis trends SHIRE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 69,0 $
Spread / Average Target 40%
EPS Revisions
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
Matt Walker Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE-20.59%44 568
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372